Royal Sense Ltd

Royal Sense Ltd's Board of Directors met on July 17, 2026, approving a significant increase in authorized share capital from ₹10 Crores to ₹20 Crores. The board also greenlit a fundraising plan of up to ₹500 Crores through various debt instruments, including NCDs, bonds, and GDRs/ADRs. Additionally, the company will explore setting up an overseas branch office and has approved the acquisition of assets up to ₹200 Crores. The Board's Report for FY26 and the notice for the 3rd Annual General Meeting were also approved.

Royal Sense Ltd has announced a Board of Directors meeting scheduled for July 17, 2026. The primary agenda items include considering and approving an increase in the company's authorized share capital and consequent alteration of the Memorandum of Association, subject to shareholder approval. Additionally, the board will discuss raising funds through various instruments like equity shares, convertible securities, or debt, via methods such as public issue, rights issue, preferential allotment, or QIP, also requiring shareholder consent. The trading window for company securities will be closed from immediate effect until 48 hours after the board meeting concludes, in compliance with SEBI regulations.

Rishabh Arora, a promoter of Royal Sense Ltd, has disclosed the creation of an encumbrance over 10,00,000 equity shares, representing 18.69% of the total share capital. This action was taken on July 2, 2026, with the shares pledged as security for financial assistance to Comfort Securities Limited. The disclosure was made to the stock exchanges on July 4, 2026, in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Post-encumbrance, Rishabh Arora's direct holding in the company remains significant.

Royal Sense Ltd's Board of Directors approved the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. The board also approved revisions to the Royal Sense Employee Stock Option Plan 2024 and constituted a Funds Management Committee and a Procurement and Compliance Approval Committee. Remuneration for key managerial personnel was also approved.

Royal Sense Ltd's board meeting on May 25, 2026, approved audited standalone and consolidated financial results for the half-year and financial year ended March 31, 2026. The board also approved revisions to the Royal Sense Employee Stock Option Plan 2024, subject to member approval. Additionally, it constituted a Funds Management Committee and a Procurement and Compliance Approval Committee. Remuneration for key managerial personnel was also approved, pending member consideration.

Royal Sense Ltd has scheduled a Board of Directors meeting on May 25, 2026, to consider and approve the audited standalone and consolidated financial results for the half and full financial year ended March 31, 2026. The board will also consider revisions to the Royal Sense Employee Stock Option Plan 2024. The trading window for dealing in the company's equity shares has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the audited financial results.

Royal Sense Ltd has announced the launch of new pharmaceutical products, available for sale from May 20, 2026. The product range includes STERGICLAV 625, SMARTYCALV 625, STERPRAX, STERGIPAM MD, STERGICET, STERPIDEM MD, and STERGIC BLOOD PRESSURE MONITOR. The company highlights the features and benefits of STERGICLAV 625 and SMARTYCALV 625, emphasizing their broad-spectrum antibacterial activity and effectiveness against resistant bacteria. The company caters to the domestic market.

Royal Sense Ltd has announced the launch of 17 new pharmaceutical products, available for sale from April 27, 2026. The new product line includes various health supplements such as Cholecalciferol Nano Shot, Stergivita Caps/Syrup, Lycoseven Caps/Syrup, and several 'Shakti' and 'Detox' products. These products are categorized as pharmaceuticals and are intended for the domestic market. The company provided detailed information for its "New Cholecacirol Nano Shot," highlighting its sugar-free, fast-absorbing nano-technology formulation for Vitamin D3 deficiency, targeting a significant and growing market segment in India (estimated ₹250-350 Crore for oral solution/nano shot Vitamin D3, growing at 12-15% CAGR). The launch aims to capitalize on the high prevalence of Vitamin D deficiency and increasing demand for convenient dosage forms.

Royal Sense Ltd has replied to a clarification sought on the movement in the price of their shares across exchanges. The company has informed that all material information that may have a bearing on their operations or performance has been regularly disclosed to the Stock Exchange. They reiterate that the movement in the price of their securities is purely due to market conditions and are market-driven. The company will continue to inform the stock exchanges about any price-sensitive information as required.

Royal Sense Ltd has announced the closure of its trading window for insiders, designated persons, and their immediate relatives. The closure will be effective from Wednesday, 01st April, 2026 until 48 hours after the declaration of the audited standalone financial results for the half year and financial year ending on March 31, 2026. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Policy on Code of Conduct for Regulating, Monitoring & Reporting of Trades and Prevention of Insider Trading. The date of the board meeting to consider the audited financial results will be intimated separately.